Brind.

Soleno Therapeutics received a Zacks Rank of #2 (Buy) and a Momentum Style Score of A on July 26, 2025.

2 reports, 1 independent Updated Jul 26
Gone quiet
Reports
2
Developments
1
Repetition
50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Soleno Therapeutics received a Zacks Rank of #2 (Buy) and a Momentum Style Score of A on July 26, 2025.

Who's involved

What this event is mainly about
Soleno Therapeutics (United States)

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
  • ZacksSoleno Therapeutics, Inc. (SLNO) is a Great Momentum Stock: Should You Buy? Momentum investing revolves around the idea of following a stock's recent trend in either direction. In "long context," inv
  • ZacksHere's What Could Help Soleno Therapeutics (SLNO) Maintain Its Recent Price Strength Most of us have heard the dictum "the trend is your friend." And this is undeniably the key to success when it com